Sun Pharma Advanced Research Share Price Soars 20% After Court Ruling

Sun Pharma Advanced Research Company share price (NSE: SPARC) surged 20% to ₹161.10 in Tuesday’s trade, even as the broader market stayed weak. Nearly 27.7 million shares, or 8.5% of the company's equity, were traded across NSE and BSE, showing strong investor interest. Buy orders of over 6.2 lakh shares were still pending by early afternoon.

The stock had earlier touched a 52-week low of ₹109.2 on March 3, 2025, and a 52-week high of ₹240.95 on December 16, 2024.

Why Did SPARC Shares Jump?

SPARC announced that the US District Court for the District of Columbia granted a summary judgment in its favour regarding the Priority Review Voucher (PRV) for its drug Sezaby.

The court ruled that the FDA’s decision to withhold the PRV was incorrect, stating that no earlier drug containing phenobarbital sodium had been approved under that definition. The FDA now has 60 days to appeal.

Sezaby is a special formulation of phenobarbital sodium used to treat neonatal seizures, approved by the USFDA.

About SPARC

SPARC is a clinical-stage biopharmaceutical company focused on improving patient outcomes through innovative therapies and advanced drug delivery systems.

SPARC’s Future Outlook

In its FY25 annual report, the company said it is entering a more focused phase. Its immediate priorities include progressing 2 key assets—SCD-153 and SBO-154. SPARC plans to maintain flexibility through partnerships and selective investments in the rest of its pipeline.

The company will also closely track regulatory trends, market access, and capital needs while continuing to strengthen its funding strategy. With a lean structure and a sharper portfolio, SPARC aims to deliver long-term value to both patients and shareholders.

Also Read: E2W Market Saw a Fall of 20% in November 2025: TVS Reclaimed Top Seller with 20% Market Share!

Government Support for Pharma R&D

The Indian government is also boosting pharmaceutical innovation through policies and incentives. Key initiatives include fiscal benefits for R&D units, easier regulatory procedures, and a national policy focused on pharma-medtech innovation.

A major push is the Research Linked Incentive (RLI) scheme, which provides $600 million (FY24–FY28) for developing new chemical entities, biologics, complex generics, biosimilars, and orphan drugs.

Conclusion

SPARC’s sharp 20% rally was driven by a favourable US court decision and strong investor interest. With a focused strategy, promising drug candidates, and government support for pharma R&D, the company appears well-positioned for future growth.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.